Squarepoint
SMMT icon

Squarepoint’s Summit Therapeutics SMMT Stock Holding History

Squarepoint’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.2M Buy
1,590,736
+976,859
+159% +$17.3M 0.03% 624
2026
Q1 		$11.6M Sell
613,877
-101,533
-14% -$1.64M 0.01% 994
2025
Q4 		$12.5M Buy
715,410
+605,584
+551% +$11.4M 0.01% 978
2025
Q3 		$2.27M Sell
109,826
-181,396
-62% -$4.4M ﹤0.01% 1994
2025
Q2 		$6.2M Buy
+291,222
New +$6.64M 0.01% 1324
2025
Q1 		– Sell
-18,347
Closed -$368K – 5340
2024
Q4 		$327K Buy
+18,347
New +$356K ﹤0.01% 4086
2024
Q3 		– Sell
-86,064
Closed -$671K – 4658
2024
Q2 		$671K Buy
86,064
+56,614
+192% +$306K ﹤0.01% 2856
2024
Q1 		$122K Buy
+29,450
New +$117K ﹤0.01% 3753
2023
Q2 		– Sell
-285,578
Closed -$500K – 3970
2023
Q1 		$500K Buy
+285,578
New +$779K ﹤0.01% 2296
2021
Q1 		– Sell
-12,751
Closed -$60K – 3572
2020
Q4 		$60K Buy
+12,751
New +$54K ﹤0.01% 2788

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Squarepoint's SMMT Position: Q2 2026 in Review

Squarepoint increased its Summit Therapeutics (SMMT) stake by 159% in Q2 2026, buying an estimated $17.3M and bringing the position to 1,590,736 shares worth $23.2M. The position accounts for 0.03% of the portfolio, ranked #624.

Squarepoint first reported a position in SMMT in Q4 2020 and has held it in 10 quarters since. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Squarepoint held 1,590,736 shares of Summit Therapeutics worth $23.2M as of Q2 2026.
  • Squarepoint bought 976,859 Summit Therapeutics shares in Q2 2026, an estimated $17.3M.
  • Summit Therapeutics made up 0.03% of Squarepoint's portfolio in Q2 2026, its #624 holding.
  • Squarepoint first reported a position in Summit Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.